Vertex Pharmaceuticals (NASDAQ: VRTX) has been reigning as the global leader in cystic fibrosis (CF) treatment, drawing billions in earnings from this specialty area. Diversification has been a key goal for the biotech giant in recent years as it seeks to expand its scope beyond CF treatment.
Vertex’s upcoming product, VX-548, is targeting a common woe – pain. The company is poised to submit VX-548 for regulatory approval by mid-year. However, a new entrant, Latigo Biotherapeutics, has emerged from stealth mode and garnered attention with a strikingly similar pain candidate, raising questions about the potential impact on Vertex’s prospects in the billion-dollar pain market.
Latigo Biotherapeutics recently secured $135 million in Series A financing to propel its pain candidate through phase 1 trials. The arrival of this upstart has prompted a closer look at Vertex’s position in the chronic pain treatment landscape. Is Vertex facing a serious threat to its dominance in this market? Let’s delve deeper and find out.
Image source: Getty Images.
Challenges with Current Pain Medications
The market for pain management is massive and steadily expanding, with a projected value of over $108 billion by 2032, according to Global Market Insights. This growth is driven by limitations in current over-the-counter non-opioid options, which are often inadequate for managing intense pain levels and can lead to severe side effects such as liver toxicity. On the other hand, while prescription opioids are effective, they come with a risk of addiction.
Against this backdrop, a breakthrough non-opioid pain treatment that not only outperforms existing drugs in terms of safety but also matches their efficacy is poised to claim a substantial share of this lucrative market.
Vertex’s VX-548 and Latigo’s LTG-001 both target NaV1.8, a crucial sodium channel in pain signaling. Vertex’s VX-548 has recently demonstrated positive results in pivotal trial data, showing statistically significant improvement in pain compared to the placebo. While the candidate’s superiority over the most commonly prescribed opioid combination remains unproven, its potential to address a wide range of pain conditions positions it as a formidable contender in the pain management arena.
Latigo’s Pain Candidate
Latigo’s LTG-001 is currently undergoing phase 1 trials, supported by the substantial Series A financing. As Latigo progresses with its pain candidate targeting acute and chronic pain, Vertex is advancing towards regulatory approval for moderate-to-severe acute pain with VX-548, followed by the pursuit of chronic nerve pain treatment. With positive phase 2 data already reported for diabetic peripheral neuropathy, Vertex stands on the cusp of pivotal trials.
Returning to the question at hand: Could Latigo’s emergence pose a threat to Vertex? The answer is no, for several compelling reasons.
Firstly, Vertex is significantly closer to commercialization and could secure a first-to-market advantage if all goes as planned. Secondly, as a well-established and profitable entity, Vertex possesses the infrastructure for manufacturing, logistics, and sales, crucial for the swift launch of new products, leveraging its experience from the CF domain to expand into new therapeutic areas.
Furthermore, the pain management market is capacious enough to accommodate multiple successful players. Even if a new player like Latigo enters the commercialization fray in the coming years, it is unlikely to disrupt Vertex’s standing in the market.
All signs point to Vertex maintaining its stronghold in the billion-dollar pain market, just as it has in the realm of CF treatment. This reaffirms a positive outlook for Vertex’s investors.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for two decades, Motley Fool Stock Advisor, has more than tripled the market.*
They just revealed what they believe are the 10 best stocks for investors to buy right now… and Vertex Pharmaceuticals made the list — but there are 9 other stocks you may be overlooking.
See the 10 stocks
*Stock Advisor returns as of February 12, 2024
Adria Cimino has positions in Vertex Pharmaceuticals. The The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
